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http://dx.doi.org/10.1016/j.ccr.2014.04.005SUMMARYPancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal myofibroblasts,
but their functional contribution remains unknown. Transgenic mice with the ability to delete aSMA+ myofi-
broblasts in pancreatic cancer were generated. Depletion starting at either noninvasive precursor (pancreatic
intraepithelial neoplasia) or the PDAC stage led to invasive, undifferentiated tumors with enhanced hypoxia,
epithelial-to-mesenchymal transition, and cancer stem cells, with diminished animal survival. In PDAC
patients, fewer myofibroblasts in their tumors also correlated with reduced survival. Suppressed immune
surveillance with increased CD4+Foxp3+ Tregs was observed in myofibroblast-depleted mouse tumors.
Although myofibroblast-depleted tumors did not respond to gemcitabine, anti-CTLA4 immunotherapy
reversed disease acceleration and prolonged animal survival. This study underscores the need for caution
in targeting carcinoma-associated fibroblasts in PDAC.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a near uniformly
lethal disease with a dismal median survival of 4 to 6 months
(Hidalgo, 2010; Korc, 2007). Despite years of efforts to design
therapeutic approaches for pancreatic cancer, the use of con-
ventional chemotherapy combination regimens with modest
benefit remains the only option for the overwhelming majoritySignificance
Pancreas cancer is associatedwith large amounts of stroma co
contribution remains unknown. Specific depletion ofmyofibrob
to aggressive tumors with diminished animal survival. Fewer
patient survival. Detailed studies show that myofibroblast loss
associated with the persistence of regulatory T cells. Myofibro
immunotherapy to revive immune attack prolonged mice’s sur
blasts and suggests that targeting carcinoma-associated fib
caution.of patients who present with advanced neoplasms. Revisiting
the complex biology of PDAC in an unbiased manner is thus ur-
gently required if we are to developmore effective therapies. The
progress in generating genetically engineered mouse models
faithfully mimicking human PDAC provides a unique opportunity
to interrogate the functional contribution of the desmoplastic
stromal reaction in PDAC, a defining feature of this carcinoma,
which accounts for the majority of the tumor tissue volumemposed of collagen I andmyofibroblasts, but their functional
lasts using compound geneticmousemodels of PDAC leads
myofibroblasts in human PDAC also correlate with reduced
decreases the ability of the immune system to control cancer
blast depletion did not improve gemcitabine’s efficacy, but
vival. This study demonstrates a protective role of myofibro-
roblasts in pancreas cancer should be approached with
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Myofibroblasts in PDAC(Aguirre et al., 2003; Bardeesy et al., 2006a, 2006b; Gidekel
Friedlander et al., 2009; Hingorani et al., 2003, 2005; Hruban
et al., 2007; Ijichi et al., 2006).
The cellular component of the desmoplastic stroma in PDAC is
composed primarily of myofibroblasts, characterized by aSMA
expression (Feig et al., 2012; Rasheed et al., 2012). Recent
studies have implicated the stromaas aphysical barrier to thede-
livery of cytotoxic chemotherapies to the peritumoral milieu (Feig
et al., 2012; Provenzano et al., 2012;Whatcott et al., 2012). None-
theless, although preclinical models have demonstrated the
benefit of stromal depletion through blockade of paracrine
Hedgehog signaling in accentuating drug delivery (Olive et al.,
2009), subsequent clinical trials targeting stromal myofibroblasts
in human PDAC resulted in an apparent paradoxical accelerated
disease progression, halting clinical trials (Amakye et al., 2013).
These studies reinforced the need to critically evaluate the func-
tional contribution of stroma in the initiation and progression of
PDAC. In this regard, the functional role ofaSMA+myofibroblasts
and type I collagen in PDAC remains unknown.
RESULTS
Myofibroblast Depletion Leads to Increased Tumor
Invasion Associated with Decreased Survival
To interrogate the functional contribution of aSMA+ myofibro-
blasts in PDAC, we used a genetic strategy for selective in vivo
depletion. Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2flox/flox (PKT) mice
develop spontaneous PDAC with full penetrance that reliably re-
capitulates the clinical and histopathological features of the hu-
man disease (Ijichi et al., 2006). The mice consistently progress
from pancreatic intraepithelial neoplasia (PanIN) at 4.5 weeks
of age to invasive cancer at 6 weeks of age and die at 8 weeks
of age, without much variation (Ijichi et al., 2006). These mice
were crossed with aSMA-tk transgenic mice to selectively target
proliferating aSMA+ myofibroblasts upon systemic ganciclovir
(GCV; InvivoGen) administration (PKT; aSMA-tk mice) (LeBleu
et al., 2013). Daily GCV injections were initiated when mice
developed PanIN lesions (early) and allowed to progress to
PDAC (Figure 1A). Mice also received GCV injections starting
at the established PDAC stage (late) until they developed signif-
icant signs of illness leading to their death or requiring euthanasia
(Figure 1A). In both early and late myofibroblast depletion set-
tings, PKT mice presented with significantly more invasive, un-Figure 1. Myofibroblast Depletion Augments PDAC and Diminishes Ov
(A) Tumor progression timeline with experimental treatment time points. GCV adm
with control PKT; aSMA-tk mice.
(B) Representative micrographs of H&E stained pancreatic samples (scale bar re
(C) Pathological scores of early-depleted tumors (left: wild-type [WT], n = 5; contr
n = 17; depleted, n = 26). Significance was determined by one-way ANOVA with
(D) Necrosis penetrance of early-depleted tumors (left: WT, n = 5; control, n = 16
depleted, n = 25).
(E) Relative percentages in histological phenotypes in late depleted tumors. Con
(F) Representative micrographs (scale bar represents 50 mm) of Ki-67/aSMA
quantification (n = 4 and n = 6 for control and depleted, respectively). Arrows point
represents 25 mm).
(G) Representative micrographs (scale bar represents 100 mm) of reporter aSMA
fication (n = 3 in each group).
(H) Survival analysis of early (left) and late (right) treatment groups. GCV, GCV tre
Data are represented asmean ± SEM. Unless otherwise noted, significancewas d
significant. See also Figure S1.differentiated, and necrotic tumors when myofibroblasts were
depleted compared with control tumors (Figures 1B–1E). Immu-
nohistochemical and immunofluorescence analyses revealed an
average of 80% depletion of proliferating myofibroblasts (Fig-
ure 1F; Figures S1A and S1B available online). Direct visualiza-
tion of interstitial myofibroblasts using the aSMA-RFP transgenic
mice crossed with PKT; aSMA-tk mice also showed approxi-
mately 80% depletion of total myofibroblasts (Figure 1G). A
significant reduction in aSMA transcript level was also noted
in depleted tumors (Figure S1C). Extrapancreatic organs, such
as the kidney, lung, small bowel, heart, and liver, did not show
any depletion in aSMA+ cells (Figures S1D and S1E). Notably,
myofibroblast depletion in PDACwas associated with significant
reduction in survival, in both the early and late depletion groups
(Figure 1H). Tumor weight was significantly reduced by myofi-
broblast depletion and was associated with a reduced body
weight specifically in PDAC mice with late myofibroblast deple-
tion (Figures S1F and S1G). Mice with myofibroblast-depleted
tumors exhibit an increased frequency of pulmonary emboli,
likely contributing to diminished overall survival (Figure S1H).
Loss of one allele of Tgfbr2 (versus both in the PKT mice) in the
context of KrasG12D activation (PKTHet mice) leads to a similar
PDAC phenotype, but with a slower progression rate, with PanIN
lesions noted at 4 to 6weeks of age andPDACat 8 to 10weeks of
age (Ijichi et al., 2006). GCV treatment was initiated at the onset
of PDAC in PKTHet; aSMA-tk mice and continued until they died
or were moribund, requiring euthanasia. Depletion of myofibro-
blasts resulted in undifferentiated tumors (Figures 2A–2E) and
significantly diminished the survival of PKTHet;aSMA-tkmice (Fig-
ure 2F). Similar findings were also observedwhenmyofibroblasts
were depleted in Pdx1cre/+;LSL-KrasG12D/+;Trp53R172H/+ (KPC)
mice crossed with aSMA-tk (KPC; aSMA-tk) mice. Myofibroblast
depletion in this setting also resulted in poorly differentiated tu-
mors and significantly diminished survival (Figures S2A–S2C).
Because of the similar phenotypes of the PKT; aSMA-tk mice
andKPC; aSMA-tkmice, the remaining experiments were carried
out using the PKTmice because of their faster course of disease.
On the basis of the striking and somewhat unexpected impact
of stromal depletion on survival in PDAC models, we next as-
sessed whether a comparable impact of stromal content was
observed in the cognate human setting. Immunohistochemical
scoring for interstitial aSMA+ cells from resected PDAC of
untreated patients indicated that low aSMA is associated witherall Survival
inistration in PKT; aSMA-tk+ mice allows myofibroblast depletion, in contrast
presents 100 mm).
ol, n = 16; depleted, n = 17) and late-depleted tumors (right: WT, n = 5; control,
Tukey post hoc analysis.
; depleted, n = 22) and late-depleted tumors (right: WT, n = 5; control, n = 17;
trol, n = 17; depleted, n = 25.
dual-immunofluorescence (left, control; right, depleted) and corresponding
to double-positive cells and inserts show high-magnification images (scale bar
-RFP tumor samples (left, control; right, depleted) and corresponding quanti-
atment was initiated.
etermined using t tests (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). ns, not
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Figure 2. Decreased aSMA Correlates with Poor Prognosis and Overall Survival in Slow-Progressing Mice with PDAC and Patients with
Pancreatic Cancer
(A and B) Representative micrographs of H&E stained PKTHet tumors at 106 (control, left) and 103 (depleted, right) days old (A) (scale bar represents 100 mm) and
pathological scores (B). WT, n = 5; control, n = 6; depleted, n = 4. Significance was determined by one-way ANOVA with Tukey post hoc analysis.
(C) Relative percentages in histological phenotypes (n = 6 and n = 4, respectively, for control and depleted).
(D and E) Representative micrographs of aSMA stained pancreatic samples as in (A) (D) (scale bar represents 100 mm) and corresponding quantification (E) (n = 6
and n = 4, respectively, for control and depleted). V, vessel.
(F) Survival analysis in PKTHet mice. GCV, GCV treatment was initiated.
(G) Representative micrographs of aSMA stained pancreatic samples resected from patients in each score category: 0, 1, 2, and 3 (scale bar represents 200 mm).
(H) Survival analysis based on histopathological score (left) and aSMA score (right). Low aSMA: scores 0 and 1; high aSMA: scores 2 and 3.
Significancewas determined using theMantel-Cox test. Data are represented asmean ± SEM. Unless otherwise noted, significancewas determined using t tests
(*p < 0.05, ***p < 0.001, ****p < 0.0001). ns, not significant. See also Figure S2 and Table S1.
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Myofibroblasts in PDACworse survival, supporting the observations in the PKT and KPC
mice with myofibroblast depletion (Figure 2G; Table S1). Of note,
patients with low aSMA scores present significantly more often
with poorly differentiated cancers than tumors with well or mod-
erate differentiation (Table S1), and yet despite this correlation,
aSMA scoring offered greater significance in differential stratifi-
cation of patients for survival than histopathological grade (Fig-
ure 2H), suggesting that stromal content likely has a direct
impact on the natural history of human PDAC.
Myofibroblast Depletion Reduced Type I Collagen
Content and Altered ExtracellularMatrix Organization in
PDAC
Global gene expression profiling of tumors from PKT mice
without (control) and with myofibroblast depletion (depleted) re-
vealed differentially expressed genes associated with remodel-
ing of the extracellular matrix (ECM), epithelial-to-mesenchymal
transition (EMT), angiogenesis, and immune response (Table
S2). Comparative analyses of tumor transcriptomes revealed
4,393 differentially expressed genes in early-depleted versus
age-matched control tumors (1,682 downregulated and 2,711
upregulated genes) and 2,344 differentially expressed genes in
late-depleted versus age-matched control tumors (1,170 down-
regulated and 1,174 upregulated genes) (Figures S3A–S3D). Tu-
mor collagen content assayed by type I collagen immunostaining
(Figure 3A) was significantly decreased in myofibroblast-
depleted tumors. Masson’s trichrome staining (MTS) and
picrosirius red staining revealed a significant reorganization of
collagen fibrils, with decreased stiffness and elastic modulus in
myofibroblast-depleted tumors compared with control tumors
(Figures 3B–3D). Interestingly, collagen crosslinking and immu-
nolabeling for the collagen crosslinking enzyme lysyl oxidase
(LOX) were unchanged despite reduced stiffness of the ECM
(Figures 3E and 3F), highlighting a complex regulation of type I
collagen crosslinking mediated by multiple sources of LOX.
These results are consistent with the ability of aSMA+ myofibro-
blasts to produce type I collagen and induce fibrosis in PDAC.
Despite extensive remodeling of type I collagen ECM in myofi-
broblast-depleted tumors, hyaluronic acid (HA) binding protein
(HABP), a marker for total HA content, remained unchanged
in the myofibroblast-depleted tumors (Figure S3E). Vimentin la-
beling, however, was significantly decreased in myofibroblast-
depleted tumors (Figure S3F). Auditing of other mesenchymal
cells in the PDAC tumor stroma revealed a decrease in the
number of fibroblast-specific protein 1 (FSP1)/S100A4+ cells in
myofibroblast-depleted tumors (Figure S3G), while the number
of fibroblast activation protein (FAP)-positive cells remained un-
changed (Figure S3H). Colocalization of aSMA with FAP was not
detectable in the PDAC tumors (Figure S3H).
Myofibroblast-Depleted PDAC Displays Suppression of
Angiogenesis, Enhanced Tumor Hypoxia, EMT Program,
and Cancer Stem Cell-like Phenotype
Histopathological analyses of myofibroblast-depleted tumors
revealed highly undifferentiated, invasive-grade tumors with
enhanced necrosis (Figures 1B–1E). These features are associ-
ated with tumor hypoxia and the acquisition of an EMT program.
Myofibroblast depletion was associated with a decrease in the
number of CD31+ vessels, indicative of suppressed vessel den-sity (Figure 4A; Figures S4A–S4C). Perivascular aSMA+ cells
appear unaffected by the aSMA-tk strategy (Figure S4A). Global
gene expression profiling performed on normal pancreas fibro-
blasts and PDAC-associated fibroblasts (CAF) shows differ-
ences in pathways affecting ECM remodeling, angiogenesis,
and immune response in PDAC (Figure S4D; Table S3). RNA
sequencing analyses further validated the increased expression
of several proangiogenic factors in CAF, supporting their proan-
giogenic role in PDAC (Table S3).
Although pericyte numbers, assayed by immunostaining
analyses for the pericyte marker NG2 (Figure S4B), and vascular
leakage, determined by extravascular fluorescein isothiocyanate
(FITC)-dextran (Figure 4B; Figure S4E), were unchanged, tumor
hypoxia assayed by staining for pimonidazole adduct formation
was dramatically increased in myofibroblast-depleted tumors
compared with control tumors (Figure 4C; Figure S4F). Lineage
tracing of cancer cells using the LSL-YFP reporter together
with immunolabeling for aSMA allowed the quantitative analysis
of YFP+ cancer cells that have acquired mesenchymal features
(YFP+aSMA+ cells). Tumors with 80% depletion of aSMA+ inter-
stitial myofibroblasts showed an increase in EMT program
with increased YFP+aSMA+ cells (Figure 4D; Figure S4G) and
enhanced expression of the EMT transcriptional regulators,
Twist, Snail, and Slug (Figure 4E). The enhanced acquisition of
EMTwas associated with the loss of mucin staining (Figure S4H),
which is in alignment with the decreased histological differentia-
tion within the neoplastic glands (Figures 1B–1E). YFP+ cancer
cells from myofibroblast-depleted tumors exhibited an increase
in their capacity to form spheres in culture, a feature of cells with
EMT program and potential cancer stem cell-like phenotype
(Kalluri and Weinberg, 2009; Scheel and Weinberg, 2012) (Fig-
ure 4F; Figure S4I). Additionally, the number of CD44+CD133+
cells (suggestive of pancreatic cancer stem cells; Hermann
et al., 2007; Simeone, 2008) was enhanced in myofibroblast-
depleted tumors (Figure 4G). Fluorescence-activated cell sorted
YFP+ cells freshly isolated from myofibroblast-depleted tumors
showed enhanced tumorigenic potential when implanted in
nude mice (Figure 4H). Interestingly, cancer cells with EMT pro-
gram and expression of aSMA were not eliminated in the PKT;
aSMA-tk mice on GCV administration but increased in number
(Figure 4D). This could be explained by the observation that can-
cer cells with EMT program likely do not proliferate (Tsai et al.,
2012; Vega et al., 2004), further confirming their low-cycling-
stem-cell status. Further, although overall apoptosis was signif-
icantly increased in myofibroblast-depleted tumors (Figures S4J
and S4K), it was mostly localized within terminally differentiated
compartments, such as islets (Figure S4K).
Reduction of Fibrosis Does Not Increase the Efficacy of
Gemcitabine in PDAC
To test whether the decrease in myofibroblasts and type I
collagen content along with reduced ECM stiffness leads to
increased efficacy of gemcitabine (GEM), we treated control
and myofibroblast-depleted mice with GEM. Histopathological
score did not improve when PKT mice were treated with GEM
alone or in combination with myofibroblast depletion (Figure 5A).
TUNEL+ cell number increased with myofibroblast depletion, in-
dependent of GEM treatment, and GEM treatment alone did not
significantly increase tumor cell apoptosis (Figure 5B). Similarly,Cancer Cell 25, 719–734, June 16, 2014 ª2014 Elsevier Inc. 723
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Figure 3. PDAC ECM Is Significantly Remodeled in Myofibroblast-Depleted Tumors
(A) Representative micrographs (scale bar represents 50 mm) of collagen I and aSMA and corresponding quantification (n = 4).
(B) Representative micrographs (scale bar represents 200 mm) of MTS in late control and late deleted mice.
(C) Representative images of picrosirius red staining of PKT pancreatic tissues samples viewed under parallel (top row) and polarized (second row) light
(scale bar represents 75 mm) and representative images of stiffness distribution by atomic force microscopy measurement (AFM; third row) and quantification
(bottom row, n = 3).
(D) Quantification of the elastic modulus of tumor matrix (n = 3).
(E) Collagen crosslinking quantification (n = 4).
(F) Representative micrographs for LOX (scale bar represents 20 mm) and quantification.
Data are represented as mean ± SEM. Significance was determined using t tests (*p < 0.05, ***p < 0.001). ns, not significant. See also Figure S3 and Table S2.
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Myofibroblasts in PDACthe change in FSP1+ cells correlated only with myofibroblast
depletion and was independent of GEM treatment (Figure 5C).
Interestingly, CD31+ cell numbers decreased with GEM therapy
and decreased further with myofibroblast depletion (Figure 5D).
Standard uptake values computed from 18F-fluorodeoxyglucose
positron emission tomography (PET)/computed tomography
(CT) revealed comparable glycolysis per tumor volume in con-
trol, depleted, and GEM therapy in depleted tumors (Figure 5E).
Despite a robust decrease in collagen content associated
with myofibroblast depletion (fibrosis) (Figure 5F), GEM therapy
did not improve overall survival (Figure 5G). Further, GEM
therapy of PDAC compared with untreated mice did not result
in improved survival, as previously reported using a different
PDACmousemodel (Olive et al., 2009) (Figure 5G). GEM therapy
in myofibroblast-depleted tumors compared with myofibro-
blast-depleted tumors also failed to improve overall survival
(Figure 5G).
Myofibroblast Depletion Decreases Overall Immune
Infiltration in PDAC but Results in Increased Frequency
of FoxP3+ Treg Cells
Gene expression profiling and RNA sequence analyses
comparing control tumors with myofibroblast-depleted tumors
revealed a significant change in the expression of genes associ-
ated with tumor immunity, including those associated with acute
inflammatory responses, regulation of macrophage activation,
regulation of T cell-mediated cytotoxicity, antigen presentation,
and B cell activation (Figure 6A; Table S2). Tumors with myofi-
broblast depletion starting at the PanIN stage (early) present
with significant decreases in overall peritumoral infiltration of
CD45+ cells and CD3+ T cell and CD19+ B cell infiltration
compared with control tumors (Figure S5A). Such reductions in
T cells and B cells were not observed in established PDAC
with myofibroblast depletion (late-stage depletion) (Figure S5A).
Natural killer (NK) cell infiltration with myofibroblast depletion
was unchanged following myofibroblast depletion (Figure S5A).
In both early and late depletion settings, myofibroblast depletion
was associated with a significant suppression in the percentage
of effector T cells (Teff, CD4+Foxp3) together with an increase in
the percentage of regulator T cells (Treg, CD4+Foxp3+), leading
to an overall decrease in the Teff/Treg ratio (Figures 6B–6D).
Myofibroblast depletion resulted in increased Foxp3 and Ctla4
expression assayed by immunohistochemistry (IHC) (Figure S5B)
and real-time PCR analysis (Figure 6E), respectively, consistent
with the enhanced Treg infiltration. The cytotoxic CD8+/Treg
ratio was also decreased in the myofibroblast-depleted tumor
(Figure 6F), as well as CD3+/CD11b+ ratio (early depletion;
Figure 6G). The percentages of Teff and Treg, respectively,
correlate with disease progression and acceleration of PDAC
associated with myofibroblast depletion (Figures 6H and 6I).
The percentages of CD11b+Ly6G+ cells and granulocytes
(CD11b+Gr1+F4/80) were also increased in late myofibro-
blast-depleted tumors (Figures 6J and 6K), whereas the percent-
age of macrophages (CD11b+Gr1 F4/80+) was suppressed
(Figure 6L). The differential tumor immune infiltration in early
versus late depletion is also substantiated by distinct expression
patterns in respective tumor immune gene expression signature,
with a selectively downregulated tumor immunity gene signature
in late-depleted tumor (Figure 6A).Anti-CTLA-4 Antibody Therapy Rescues Enhanced
PDAC Progression upon Myofibroblast Depletion and
Increases Overall Survival
Myofibroblast depletion starting at early- and late-stage tumors
resulted in a decreased Teff/Treg ratio associatedwith increased
CTLA-4 expression (Figures 6D and 6E). Therefore, we tested
whether the Teff/Treg ratio in PDAC mice with myofibroblast
depletion can be rescued by CTLA-4 checkpoint blockade.
Anti-CLTA-4 antibody administration significantly improved his-
topathological scores associated with a reduction in undifferen-
tiated cancer cells (Figure 7A). Despite similar myofibroblast
depletion (Figure 7B), suggesting that anti-CTLA-4 per se did
not alter myofibroblast number, anti-CTLA-4 antibody treatment
induced tumor clearance and replacement by normal paren-
chyma in up to 25% of the organ (Figure 7C). Treatment with
anti-CTLA-4 antibodies in the setting of stromal depletion not
only resulted in a rescue of the phenotype of myofibroblast-
depleted tumors but also attenuated PDAC progression, which
was associated with a significant extension in overall survival
(an average increase of 60% in lifespan) (Figure 7D). Such elon-
gation of lifespan was associated with reduced frequency of pul-
monary emboli (Figure 7E). This was noticed in concordancewith
restored Teff and Treg percentages (Figure 7F) and diminished
tumor sphere-forming ability within remnant cancer cells in
age-matchedmice (Figure 7G). Further, the transcriptome ofmy-
ofibroblast-depleted tumors treated with anti-CTLA-4 clustered
with the expression profiles of control tumor rather than myofi-
broblast-depleted tumors, suggesting that transcriptional re-
programming accompanies the observed phenotypic rescue
(clustering using the 2,344 differentially expressed genes in
late-depleted tumors versus control) (Figure 7H). Anti-CTLA-4
alone did not alter aSMA+ content, and histopathological
analyses revealed a modest increase in the percentage of
normal parenchyma (Figures S6A and S6B). Treatment with
anti-CTLA-4 alone improved overall survival (median survival of
49.5 days, compared with 47 days in the control group), albeit
to a much lesser extent than anti-CTLA-4 treatment in com-
bination with fibrosis depletion (median survival of 65 days)
(Figure 7D).
DISCUSSION
The desmoplastic reaction is thought to represent a host defense
mechanism, similar to wound healing and tissue regeneration, to
repair or hopefully impede the conversion of a neoplastic lesion
into invasive carcinoma (Bissell and Radisky, 2001; Dvorak,
1986; Lu et al., 2012). The function of desmoplastic stroma is
likely dynamic during cancer progression, and its heterogeneous
cellular and noncellular constituents change in relation to the
evolving genetic landscape of cancer cells. In this regard, several
studies have suggested that aSMA+ myofibroblasts and type I
collagen associated with tumor fibrosis are tumor promoting in
solid tumors, including PDAC (Angeli et al., 2009; Karnoub
et al., 2007; Merika et al., 2012; Vong and Kalluri, 2011). We
demonstrate that depletion of aSMA+ myofibroblasts resulted
in multiple adverse outcomes leading to poor survival. These
results suggest that at both early and late stages of pancreatic
cancer, fibrosis associated with myofibroblasts and type I
collagen constitutes a protective response from the host ratherCancer Cell 25, 719–734, June 16, 2014 ª2014 Elsevier Inc. 725
(legend on next page)
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Myofibroblasts in PDACthan offering an oncogenic supportive role, as speculated (Arm-
strong et al., 2004; Omary et al., 2007). This conclusion is sup-
ported by the clinical correlation between high aSMA and
improved survival; a similar trend was previously reported from
analyses also performed on resected tumors from treatment-
naive patients (Wang et al., 2013). Although other studies have
also attempted to specifically address the correlation between
relative tumor content in aSMA+ myofibroblasts and PDAC pa-
tient outcomes, potential therapeutic intervention prior to tumor
resection makes interpretations unclear (Erkan et al., 2008; Mani
et al., 2008).
Myofibroblast depletion leads to extensive remodeling of the
tumor ECM, with a significant decrease in tumor tissue stiffness
and total collagen content. Myofibroblasts contribute to the pro-
duction of type I collagen, albeit likely not all of it. Contrary to
previous assumptions, myofibroblasts do not contribute to the
total production of LOX, an enzyme responsible for crosslinking
of type I collagen. In this regard, we did not observe a difference
in crosslinking, despite significant depletion and reorganization
of tumor-associated collagen. Therefore, cancer cells or other
stromal cells may compensate LOX expression. Similar to
LOX, myofibroblast depletion did not affect HA content of the
tumors, suggesting a nonmyofibroblast source for this matrix
molecule. Targeting HA using PEGPH20, a modified enzyme
that degrades HA, yielded promising results when combined
with GEM (Jacobetz et al., 2013; Provenzano et al., 2012). In
our study, ECM remodeling and the significant reduction in
collagen content via myofibroblast depletion did not improve
the treatment efficacy of GEM. Therefore, PDAC-associated
myofibroblasts and type I collagen do not appear to serve as
physical barriers to the exposure of cancer cells to GEM.
In this regard, the potential role of HA, independent of type I
collagen, in determining interstitial fluid pressure in PDAC tissue
needs further mechanistic unraveling, and clinical trials with
PEGPH20 will offer more insights in the future (Provenzano
et al., 2012).
As noted above, significant depletion of myofibroblasts and
type I collagen did not alter vessel permeability and perfusion.
GEM efficacy was unaltered in myofibroblast and type I
collagen-depleted tumors, suggesting that the increased effi-
cacy observed in preclinical models treated with GEM and
Smoothened inhibitor IPI-926 was likely due to mechanisms in-
dependent of myofibroblasts and type I collagen (Olive et al.,Figure 4. Myofibroblast-Depleted Tumors Display Increased Invasion
(A) Representative micrographs (scale bar represents 100 mm) of CD31 staining
compartment, where CD31+ vessels are primarily found.
(B) Representative micrographs (scale bar represents 100 mm) and correspondin
(C) Representative micrographs (scale bar represents 100 mm) of hypoxia indica
(D) Representative micrographs (scale bar represents 50 mm) of aSMA+ cells in t
(n = 4). White arrowheads point to aSMA+YFP+ cells.
(E) Relative Twist, Snail, and Slug expression in tumors.
(F) Representative micrograph (scale bar represents 100 mm) of YFP+ tumor spher
and corresponding quantification (n = 15).
(G) Representative scatterplot and quantification of percentage CD44+CD133
CD44+CD133+; Q3: CD44CD133+; Q4: CD44CD133.
(H) Tumorigenic ability of YFP+ cells determined by limiting dilution assay. For e
myofibroblast depleted tumors, and data are presented as the number of mice d
Data are represented as mean ± SEM. Unless otherwise noted, significance was d
See also Figure S4 and Table S3.2009). It is likely that Smoothened inhibition was not myofibro-
blast specific and could also have affected other stromal cells,
such as endothelial cells. In this regard, further analysis of the
failed clinical trials could shed further light on this matter
(Amakye et al., 2013). It is possible that if higher doses of IPI-
926 combined with prolonged treatment period were used in
the preclinical setting, potential adverse effects may have been
encountered (Olive et al., 2009; Amakye et al., 2013). Neverthe-
less, our direct approach of targeting myofibroblasts and the
associated fibrosis offers further insights into the complexity
of using pharmacological targeting to derive specific answers
related to target cells in tumors (Olive et al., 2009).
An interesting corollary that emerges from this study is
the dominant contribution of cell division in the accumulation
of myofibroblasts in PDAC. The origin of myofibroblasts in
PDAC may be diverse (Phillips, 2012; Scarlett et al., 2011),
yet using the aSMA-tk strategy to ablate proliferating myofibro-
blasts, we show 80% depletion of these cells, which account
for the majority of myofibroblasts in PDAC tumors. These
results offer an opportunity to speculate that drugs such as
GEM and paclitaxel, which target proliferating cancer cells,
may also target proliferating myofibroblasts. Such dual target-
ing may likely compromise the efficacy of GEM over time,
because of progressive depletion of protective fibrosis along
with proliferating cancer cells, resulting in the eventual emer-
gence of resistant cancer cells with EMT program and stem
cell-like phenotype.
Intratumoral hypoxia was dramatically increased in myofibro-
blast-depleted tumors. Decreased tumor vasculature, despite
intact vessel structural integrity and permeability status, may
have directly contributed to the increased tumor hypoxia when
myofibroblasts are depleted, consequently promoting enhanced
invasiveness and an undifferentiated phenotype of cancer cells
(Cheresh and Stupack, 2008; Cooke et al., 2012; Pa`ez-Ribes
et al., 2009). Impaired paracrine signaling between myofibro-
blasts and cancer cells and alteration of ECMmicroenvironment
due to myofibroblast depletion might also have directly contrib-
uted to changes in cancer cells, lending to the acquisition of
EMT program, stem cell-like phenotype, and an undifferentiated
state. Many studies have indeed suggested that altered matrix
microenvironment can influence the acquisition of epigenetic
changes in epithelial cells (Bissell et al., 2005; Grassian et al.,
2011; Guerra et al., 2011).Associated with Intratumoral Hypoxia
and corresponding quantification (n = 4). Dashed lines delineate the stromal
g quantification (n = 4) of CD31 cells and intratumoral FITC-dextran leakage.
tor, Hypoxyprobe, and corresponding quantification (n = 4).
umors with YFP+ linage tagged cancer cells and corresponding quantification
es (insert shows higher magnification micrograph, scale bar represents 25 mm)
+ cancer cells (control: n = 2; depleted: n = 3). Q1: CD44+CD133; Q2:
ach cell dose, six mice were injected with YFP+ cancer cells from control or
isplaying tumors. Significance was assayed using c2 tests.
etermined using t tests (*p < 0.05, **p < 0.01, ****p < 0.0001). ns, not significant.
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the composition of the immune infiltrate in the tumor microenvi-
ronment. The interplay between cancer-associated fibroblasts
and immune cells has long been recognized as a major contrib-
utor of cancer development (Coussens and Werb, 2002; Erez
et al., 2010; Kalluri and Zeisberg, 2006). Here, we demonstrate
that the immune response (innate and adaptive) associated
with PDAC tumors was significantly impaired when fibrosis
was reduced starting at the PanIN stage or at the PDAC stage.
Myofibroblast-depleted tumors are associated with a decreased
Teff/Treg ratio and a significant elevation in Ctla4 expression.
Myofibroblast depletion coupled with inhibition of checkpoint
blockade using anti-CTLA-4 antibodies significantly ameliorated
tumor burden in mice with established PDAC and improved
overall survival. Our data suggest that although myofibroblast
depletion results in the suppression of immune surveillance, an
opportunist immune profile dominated by suppressor T cells
emerges in the tumor, offering a viable checkpoint blockade
target using anti-CTLA-4 antibodies. Although this antibody
showsmarginal efficacy in control PDACmice with normal levels
of fibrosis, depletion of fibrosis unravels more robust efficacy,
likely because of significant changes in the microenvironment.
Small proof-of-concept trials with ipilimumab have revealed
some anecdotal responses (Royal et al., 2010), and our study
suggests that stratifying patients on the basis of their fibrosis
scores might offer better responses. This is supported by the
fact that ipilimumab showed dramatic efficacy inmetastatic mel-
anoma (Robert et al., 2011), a cancer with low levels of overall
stroma.
In summary, our study, together with other ongoing efforts
to elucidate pancreatic tumor immunity and immunotherapy
(Bayne et al., 2012; Clark et al., 2007; Hiraoka et al., 2006; Rob-
erts et al., 2013; Vonderheide et al., 2013), will likely offer insights
into potential efficacy of combination therapies involving immu-
notherapy in patients with pancreas cancer.
EXPERIMENTAL PROCEDURES
Animal Studies
The disease progression and genotyping for the PKT mice was previously
described (Ijichi et al., 2006). PKT mice were crossed to R26-LSL-EYFP
(purchased from Jackson Laboratory), aSMA-tk (LeBleu et al., 2013), and
aSMA-RFP (LeBleu et al., 2013) mice. Mice received daily intraperitoneal
(i.p.) injections with 50 mg/kg body weight of GCV at 4 to 4.5 weeks of age
(30.3 ± 1.7 days) for 14 days or less (early depletion) or at 6 weeks of age
(40.7 ± 1.7 days) for 10 days or less (late depletion). One hour prior to sacrifice,
mice were injected i.p. with 60 mg/kg body weight pimonidazole (Hypoxyp-Figure 5. GEM Treatment Does Not Improve Survival of Mice with Myo
(A) Representative micrographs of H&E stained pancreatic samples (scale bar re
Control, n = 16; depleted, n = 17; GEM, n = 8; and GEM depleted, n = 8.
(B) Representative micrographs (scale bar represents 200 mm) of the apoptosis m
(C) Representative micrographs (scale bar represents 100 mm) of FSP1 IHC and
(D) Representative micrographs (scale bar represents 100 mm) of CD31 IHC and
(E) Representative 18F-FDG PET/CT (top, frontal section; bottom, sagittal sectio
group).
(F) Hydroxyproline release reflecting collagen content in control and myofibrobla
t tests.
(G) Survival analyses of indicated experimental groups.
Data are represented as mean ± SEM. Unless otherwise noted, significance wa
**p < 0.01). ns, not significant.robe). KPC mice were previously described (Hingorani et al., 2005) and
crossed to aSMA-tkmice. KPCmicewere treatedwithGCV starting at 7weeks
of age (49 ± 2.5 days). GEM (50 mg/kg body weight; LC Laboratories) was given
i.p. at day 1 and day 7, either alone or in combination with GCV. An initial
200 mg anti-CTLA-4 (BioXCell, clone 9H10, BE0131) antibody or 200 mg ham-
ster immunoglobulin G (IgG) (BioXCell, BE0091) in 200 ml PBS was adminis-
tered i.p., followed by two injections of 100 mg anti-CTLA-4 or 100 mg hamster
IgG in 100 ml PBS every other day. All mice were housed under standard hous-
ing conditions at the Beth Israel Deaconess Medical Center (BIDMC) and MD
Anderson Cancer Center (MDACC) animal facilities, and all animal procedures
were reviewed and approved by the BIDMC and the MDACC institutional
animal care and use committees. Acquisition and analysis of 18F-FDG PET/
CT in mice is detailed in Supplemental Experimental Procedures.
Histology and Histopathology
Formalin-fixed tumors were submitted to the BIDMC and MDACC histology
core facilities, and paraffin-embedded sections were cut for hematoxylin
and eosin (H&E) staining and MTS. For histopathological scoring, H&E-stained
slides were scored for the penetrance of each histological hallmark on a scale
of 0 to 3. The predominant tumor phenotype gave the pathological score for the
whole tumor (1 = well differentiated, 2 = moderately differentiated, 3 = poorly
differentiated). Necrosis was also scored on a scale of 0 to 3. Lung emboli
were counted in one H&E lung section per mouse evaluated. Picrosirius red
staining for collagen was achieved using 0.1% picrosirius red (Direct Red
80; Sigma) and counterstained with Weigert’s hematoxylin. Mucin staining
was achieved using mucicarmine and metalin yellow and counter-stained
with Weigert’s hematoxylin.
IHC
Harvested tumors were formalin fixed prior to paraffin embedding. Sections 4
to 5 mm thick were deparaffinized, rehydrated, and boiled for 1 hr in 10 mM cit-
rate buffer at pH 6.0. Staining for aSMA was processed using the M.O.M. Kit
(Vector Laboratories) according to the manufacturer’s recommendations.
For all other stains, the tissue sections were blocked with 1%BSA in Tris-buff-
ered saline for 30 min prior to incubation with the primary antibody. Sections
were then incubated with biotin-conjugated anti-rabbit/rat/goat IgG and
ABC reagent (Vector Laboratories) for 30 to 45 min at room temperature.
DAB was used as a detection system (Vector Laboratories) according to the
manufacturer’s instructions. The following primary antibodies were used:
mouse anti-aSMA (Sigma) 1:200, rabbit anti-FSP1 (a gift from Dr. Eric Nielson,
Northwestern University Feinberg School of Medicine) 1:50, biotinylated anti-
HABP (Amsbio) 1:200, rabbit anti-CD31 (Abcam) 1:50, and rabbit antivimentin
(Cell Signaling) 1:100. For all stainings, DAB positivity was analyzed in five to
eight visual fields at an original magnification of 103, 203, or 403. Control
and treated mice within an experimental set (at least three mice per group)
were analyzed. All stainings were quantified using NIH ImageJ analysis
software with the same threshold for each stain; results were expressed as
percentage staining per visual field.
Immunofluorescence
Harvested tumors were embedded in O.C.T. medium (TissueTek). Frozen
sections 4 to 5 mm thick were fixed in ice-cold acetone for 20 min, blockedfibroblast-Depleted Tumors
presents 100 mm) and pathological scores of indicated experimental groups.
arker TUNEL and corresponding quantification (n = 3 in each group).
corresponding quantification (n = 4 in each group).
corresponding quantification (n = 3 in each group).
n) and associated maximum standard update value (SUVmax) (n = 3 in each
st-depleted tumors (n = 4 in each group). Significance was determined using
s determined using one-way ANOVA with Tukey post hoc analysis (*p < 0.05,
Cancer Cell 25, 719–734, June 16, 2014 ª2014 Elsevier Inc. 729
AB
C
D
E
F
G
H
I
J K L
(legend on next page)
Cancer Cell
Myofibroblasts in PDAC
730 Cancer Cell 25, 719–734, June 16, 2014 ª2014 Elsevier Inc.
Cancer Cell
Myofibroblasts in PDACwith 1% BSA in PBS, and immunostained using standard protocols. Primary
antibodies used were goat anti-collagen 1 (Southern Biotech) 1:200, mouse
anti-aSMA-FITC/mouse anti-aSMA-Cy3 (Sigma) 1:200, rat antimouse Ki-67
(abcam) 1:200, rabbit anti-FAP (Abcam) 1:200, rat anti-foxp3 (eBioscience)
1:150, rabbit anti-NG2 (Millipore) 1:200, rat anti-CD31 (BD PharMingen)
1:200, mouse 4.3.11.3 (Hypoxyprobe) 1:50, and rabbit anti-LOX (Imgenex)
1:200. Stainings for pimonidazole adduct (Hypoxyprobe) was processed using
the M.O.M. Kit according to the manufacturer’s recommendations. Apoptosis
was assessed using In Situ Cell Death Detection Kit, TMR red (Roche). DAPI
was used to stain cell nuclei.
Flow Cytometry
Weighed tumors were minced and allowed to digest in a 2 ml mixture of colla-
genase (400 U type II collagenase; Worthington) and 0.2 mg/ml DNase I in
RPMI media at 37C for 1 hr. The mixture was gently vortexed every 10 to
20 min. The tissue lysate was filtered through a 40 mm mesh prior to immuno-
staining. The resulting single-cell suspension was stained with fixable viability
dye eFluor 780, anti-CD45.2 Pacific Blue, anti-CD3 PE-Cy7, anti-CD3 Alexa
Fluor 700, anti-Foxp3 Alexa Fluor 700, anti-CD11c eFluor 615, and anti-
NK1.1 PE (all from eBioscience); anti-Granzyme B APC and anti-CD4 Qdot
605 (Life Technologies); anti-CD8 Brilliant Violet 650, anti-CD11b Brilliant
Violet 570, anti-CD19 Brilliant Violet 650, and anti-F4/80 FITC (all from
BioLegend); and anti-Ly6C APC, anti-Ly6G PE-Cy7, and anti-Ki-67 PE (BD
Biosciences). The percentage positive cells were analyzed by FlowJo and
gated on CD45 positivity. To analyze the number of CD133+CD44+ cells, the
single-cell suspension was incubated in the dark, on ice, with Aqua LIVE/
DEAD Fixable Dead Cell Stain (Molecular Probes) 1:1,000 for 30 min, followed
by staining with anti-CD44 APC 1:400 (eBioscience) and anti-CD133 PE 1:200
(eBioscience). Unstained, LIVE/DEAD only, and single stain served as control.
Doublets were gated out using forward-scatter width/height and sideward-
scatter width/height event characteristics.
Tumor Spheres and Limiting Dilution Tumor Formation Assay
Tumors were digested as described above, and cell suspension was filtered
through a 100 mm mesh. Two million cells were plated in a low-adherence
dish with 1% fetal bovine serum, Dulbecco’s modified Eagle’s medium,
and penicillin/streptomycin/amphotericin. Three to 4 weeks later, the formed
spheres were counted at 2003 magnification. For the limiting dilution
assay, flow cytometry purified YFP+ cancer cells (from PKT mice crossed to
R26-stop-EYFP reporter mice) were pelleted and resuspended in PBS prior
to subcutaneous injection in nude mice. Six nude mice received injections of
YFP+ cells (100, 1,000 or 10,000 cells) from tumors of PKT mice without myo-
fibroblast depletion (control; two donor mice were used) or with myofibroblast
depletion (depleted; two donor mice were used).
Gene Expression Profiling
Total RNA was isolated from tumors of PKT control mice (n = 3 at early stage,
n = 3 at late stage) and myofibroblast-depleted mice (n = 4 at early stage, n = 3
at late stage, n = 2 at late stage and treated with anti-CTLA4) using RNeasy
Plus Mini Kit (Qiagen) and submitted to the Microarray Core Facility at MD An-
derson Cancer Center. Gene expression analysis was performed using Mouse
Ref6 Gene Expression BeadChip (Illumina), and the Limma package from R
Bioconductor (Carey et al., 2005) was used to analyze differentially expressed
genes of myofibroblast-depleted mice versus control mice (p % 0.05, fold
change R 1.5). Gene ontology and pathway analyses of differentially ex-
pressed genes are performed using the Web-accessible program Database
for Annotation, Visualization and Integrated Discovery (Huang et al., 2009).Figure 6. Myofibroblast Depletion Results in Increased Frequency of F
(A) Heatmap of differentially regulated genes pertaining to tumor immunity in ear
(B–D) Percentage Teff (B), percentage Treg (C), and Teff/Treg ratio (D) in early- a
(E) Relative Ctla4 expression in late-treated tumors (n = 6).
(F and G) CD8+ cytotoxic T cell/Treg ratio (F) and CD3/CD11b ratio (G) in early- a
(H and I) Percentages Teff (H) and Treg (I) in normal pancreas and in early- and l
(J–L) Percentages CD11b+Ly6G+ (J), CD11b+Gr1+F4/80 (K), and CD11b+Gr1F
Data are represented as mean ± SEM. Significance was determined using t tests,
using one-way ANOVA with Tukey post hoc analysis (*p < 0.05, **p < 0.01, **p <Pathways that enrich differentially expressed genes are selected (p < 0.05).
For RNA sequencing analyses, sequencing of the whole transcriptome was
performed using the SOLiD system. Lifescope Genomic Analysis Software
version 2.5.1 was used to map the raw data to the mouse genome (build
mm10) and to quantify the counts per gene. The count data were used to
perform differential expression analysis using the R package, DEseq. Quanti-
tative real-time PCR analyses are detailed in Supplemental Experimental
Procedures.
Vascular Leakage
Vascular leakage was assayed and quantified as previously described (Cooke
et al., 2012). Quantification was performed using a grading system ranging
from 0 to 5, representing 0% to 100% extravascular FITC-dextran. Results
were plotted as scores.
Clinical Studies
Resected tumors were obtained from 53 patients (Table S1) with invasive
pancreatic adenocarcinoma who underwent surgical resection at Johns Hop-
kins Hospital after approval by the Johns Hopkins Hospital institutional review
board (IRB). The cases were obtained under an IRB-exempt protocol. Clinical
information was obtained from the electronic medical records. Tissue sec-
tions from paraffin-embedded specimens were stained for aSMA (Sigma) as
described above, and staining intensity was scored blinded. Each tissue sec-
tion was surveyed entirely for aSMA stain intensity in interstitial fibroblasts.
aSMA+ vessels of all sizes were easily distinguishable from interstitial fibro-
blasts. Overall, few aSMA+ vessels were detected in the tumors, and these
were not included in the score. A scale of 0 to 3 was used (0 = no detected
staining, 1 =weak staining, 2 =moderate staining, 3 = strong staining). Patients
were then divided into two groups: a ‘‘low aSMA’’ group, as defined by scores
of 0 and 1, and a ‘‘high aSMA’’ group, as defined by scores of 2 and 3. Kaplan-
Meier plots were drawn for each group and statistical differences evaluated
using the log rank Mantel-Cox test.
Statistics
Statistical analyses of pathological scores, flow cytometry, and immunohisto-
chemical quantifications were performed by using Student’s t test, one-way
ANOVA, or Fisher’s exact test with GraphPad Prism (GraphPad Software).
Limiting dilution assay was evaluated using SPSS (SPSS) with chi-square
tests. For survival analyses, Kaplan-Meier plots were drawn and statistical
differences evaluated using the log rank Mantel-Cox test. A p value < 0.05
was considered statistically significant.
ACCESSION NUMBERS
The microarray data are deposited at Gene Expression Omnibus under
accession numbers GSE52812 (gene expression changes comparing
pancreas tumors from PKT mice with pancreas tumors from PKT; aSMA-tk
mice) and GSE55871 (gene expression changes comparing myofibroblasts
from pancreas tumors of PKT mice with myofibroblasts from pancreas tumors
of PKT; aSMA-tk mice).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.04.005.oxP3+ Treg Cells in PDAC
ly- and late-treated tumors.
nd late-treated tumors.
nd late-treated tumors.
ate-treated tumors.
4/80+ (L) cells in late-treated tumors.
except for multiple-group comparisons, for which significance was determined
0.001, ****p < 0.0001). ns, not significant. See also Figure S5.
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